Logo image of CLRB

CELLECTAR BIOSCIENCES INC (CLRB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CLRB - US15117F8804 - Common Stock

3.65 USD
-0.1 (-2.54%)
Last: 1/15/2026, 8:00:00 PM
3.56 USD
-0.09 (-2.47%)
After Hours: 1/15/2026, 8:00:00 PM
Fundamental Rating

2

Taking everything into account, CLRB scores 2 out of 10 in our fundamental rating. CLRB was compared to 528 industry peers in the Biotechnology industry. While CLRB seems to be doing ok healthwise, there are quite some concerns on its profitability. CLRB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year CLRB has reported negative net income.
  • In the past year CLRB has reported a negative cash flow from operations.
  • In the past 5 years CLRB always reported negative net income.
  • CLRB had a negative operating cash flow in each of the past 5 years.
CLRB Yearly Net Income VS EBIT VS OCF VS FCFCLRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • With a Return On Assets value of -128.91%, CLRB is not doing good in the industry: 80.68% of the companies in the same industry are doing better.
  • CLRB's Return On Equity of -201.04% is on the low side compared to the rest of the industry. CLRB is outperformed by 67.99% of its industry peers.
Industry RankSector Rank
ROA -128.91%
ROE -201.04%
ROIC N/A
ROA(3y)-220.55%
ROA(5y)-150.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLRB Yearly ROA, ROE, ROICCLRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

  • CLRB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLRB Yearly Profit, Operating, Gross MarginsCLRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

  • The number of shares outstanding for CLRB has been increased compared to 1 year ago.
  • Compared to 5 years ago, CLRB has more shares outstanding
  • There is no outstanding debt for CLRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLRB Yearly Shares OutstandingCLRB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
CLRB Yearly Total Debt VS Total AssetsCLRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • CLRB has an Altman-Z score of -29.56. This is a bad value and indicates that CLRB is not financially healthy and even has some risk of bankruptcy.
  • CLRB has a Altman-Z score of -29.56. This is amonst the worse of the industry: CLRB underperforms 86.74% of its industry peers.
  • There is no outstanding debt for CLRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -29.56
ROIC/WACCN/A
WACCN/A
CLRB Yearly LT Debt VS Equity VS FCFCLRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

  • A Current Ratio of 2.77 indicates that CLRB has no problem at all paying its short term obligations.
  • CLRB has a worse Current ratio (2.77) than 67.23% of its industry peers.
  • A Quick Ratio of 2.77 indicates that CLRB has no problem at all paying its short term obligations.
  • CLRB has a worse Quick ratio (2.77) than 65.15% of its industry peers.
Industry RankSector Rank
Current Ratio 2.77
Quick Ratio 2.77
CLRB Yearly Current Assets VS Current LiabilitesCLRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 79.78% over the past year.
EPS 1Y (TTM)79.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CLRB will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.61% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y68%
EPS Next 2Y33.87%
EPS Next 3Y22.96%
EPS Next 5Y14.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLRB Yearly Revenue VS EstimatesCLRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
CLRB Yearly EPS VS EstimatesCLRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -1K -2K -3K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CLRB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLRB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLRB Price Earnings VS Forward Price EarningsCLRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLRB Per share dataCLRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CLRB's earnings are expected to grow with 22.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.87%
EPS Next 3Y22.96%

More info and screens

0

5. Dividend

5.1 Amount

  • CLRB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CELLECTAR BIOSCIENCES INC

NASDAQ:CLRB (1/15/2026, 8:00:00 PM)

After market: 3.56 -0.09 (-2.47%)

3.65

-0.1 (-2.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-11
Inst Owners7.01%
Inst Owner Change0%
Ins Owners0.58%
Ins Owner Change0%
Market Cap15.48M
Revenue(TTM)N/A
Net Income(TTM)-18.86M
Analysts80
Price Target47.94 (1213.42%)
Short Float %2.62%
Short Ratio0.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.04%
Min EPS beat(2)14.78%
Max EPS beat(2)45.31%
EPS beat(4)4
Avg EPS beat(4)39.84%
Min EPS beat(4)14.78%
Max EPS beat(4)83.31%
EPS beat(8)5
Avg EPS beat(8)26.48%
EPS beat(12)7
Avg EPS beat(12)17.37%
EPS beat(16)9
Avg EPS beat(16)12.83%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-44.05%
EPS NQ rev (1m)6.15%
EPS NQ rev (3m)26.81%
EPS NY rev (1m)3.71%
EPS NY rev (3m)9.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.65
P/tB 1.65
EV/EBITDA N/A
EPS(TTM)-10.8
EYN/A
EPS(NY)-7.67
Fwd EYN/A
FCF(TTM)-7.04
FCFYN/A
OCF(TTM)-7.02
OCFYN/A
SpS0
BVpS2.21
TBVpS2.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -128.91%
ROE -201.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-220.55%
ROA(5y)-150.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.63%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.77
Quick Ratio 2.77
Altman-Z -29.56
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)212.71%
Cap/Depr(5y)154.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.25%
EPS Next Y68%
EPS Next 2Y33.87%
EPS Next 3Y22.96%
EPS Next 5Y14.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y40.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.38%
OCF growth 3YN/A
OCF growth 5YN/A

CELLECTAR BIOSCIENCES INC / CLRB FAQ

Can you provide the ChartMill fundamental rating for CELLECTAR BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 2 / 10 to CLRB.


What is the valuation status of CELLECTAR BIOSCIENCES INC (CLRB) stock?

ChartMill assigns a valuation rating of 1 / 10 to CELLECTAR BIOSCIENCES INC (CLRB). This can be considered as Overvalued.


Can you provide the profitability details for CELLECTAR BIOSCIENCES INC?

CELLECTAR BIOSCIENCES INC (CLRB) has a profitability rating of 0 / 10.


Can you provide the financial health for CLRB stock?

The financial health rating of CELLECTAR BIOSCIENCES INC (CLRB) is 5 / 10.